Saturday 17 October 2026
Export DNA’s income statement to Excel — free account
Ginkgo Bioworks Holdings, Inc.
In the quarter to June 2026, revenue fell 48.5%, EPS grew 31.8% and free cash flow fell 16.4%, each against the same quarter a year earlier.
10.27
1.49
−12.67%
Follow DNA
Target Price Range
Analyst price targets
Free accountTen years at a glance Fiscal years to December
| Group | Line | 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | Trend | 2026e | 2027e | 2028e |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Price, $ | |||||||||||||||
| Price, $ | Low | — | — | — | — | — | 316.40 | 62.80 | 44.80 | 5.26 | 5.00 |
Analyst estimates 2026–2028 Powerpack |
|||
| High | — | — | — | — | — | 634.56 | 350.80 | 101.80 | 68.80 | 17.58 | |||||
| People | |||||||||||||||
| People | Employees | — | — | — | — | 2 | 641 | 1,292 | 1,218 | 834 | 485 | ||||
| Revenue/emp, $m | — | — | — | 0.00 | 38.33 | 0.49 | 0.37 | 0.21 | 0.27 | 0.35 | |||||
| Income, $m | |||||||||||||||
| Income, $m | Revenue | — | — | — | 54 | 77 | 314 | 478 | 251 | 227 | 170 | ||||
| Gross margin, % | — | — | — | 100.00 | 79.64 | 58.68 | 57.25 | 78.52 | 80.38 | 72.39 | |||||
| EBT | — | — | — | (120) | (125) | (1,838) | (2,121) | (893) | (548) | (314) | |||||
| EBT margin, % | — | — | — | (221.16) | (162.85) | (585.69) | (444.08) | (355.11) | (241.15) | (184.30) | |||||
| Net income | — | 0 | — | (120) | (127) | (1,837) | (2,106) | (893) | (547) | (313) | |||||
| Depreciation | — | — | — | 11 | 14 | 29 | 43 | 71 | 111 | 56 | |||||
| Per share, $ | |||||||||||||||
| Per share, $ | Revenue | — | — | — | 1.89 | 2.41 | 9.23 | 11.38 | 5.17 | 4.38 | 3.07 | ||||
| Earnings | — | — | — | (4.17) | (3.98) | (54.00) | (50.00) | (18.40) | (10.54) | (5.64) | |||||
| Cash flow | — | — | — | (1.55) | (4.26) | (7.47) | (6.01) | (6.08) | (6.16) | (3.08) | |||||
| Capex | — | — | — | (0.77) | (1.81) | (1.66) | (1.25) | (0.75) | (1.19) | (0.13) | |||||
| Free cash flow | — | — | — | (2.33) | (6.08) | (9.13) | (7.25) | (6.83) | (7.35) | (3.21) | |||||
| Book value | — | — | — | 0.00 | 14.75 | 46.10 | 41.36 | 22.57 | 13.80 | 9.17 | |||||
| Shares, m | — | — | — | 29 | 32 | 34 | 42 | 49 | 52 | 55 | |||||
| Valuation, × | |||||||||||||||
| Valuation, × | P/E | — | — | — | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | ||||
| P/S | — | — | — | 0.00 | 0.00 | 36.01 | 5.55 | 12.91 | 2.24 | 2.71 | |||||
| P/B | — | — | — | 2,611.53 | 2,611.53 | 7.21 | 1.53 | 2.96 | 0.71 | 0.91 | |||||
| EV/Sales | — | — | — | 0.00 | 0.00 | 31.14 | 2.92 | 9.40 | 0.03 | 0.58 | |||||
| EV/FCF | — | — | — | (95.45) | (95.45) | (31.49) | (4.59) | (7.12) | (0.02) | (0.55) | |||||
| Cash, $m | |||||||||||||||
| Cash, $m | Operating cash flow | — | — | — | (45) | (136) | (254) | (252) | (295) | (320) | (171) | ||||
| Capex | — | — | — | (22) | (58) | (57) | (52) | (36) | (62) | (7) | |||||
| Free cash flow | — | — | — | (67) | (194) | (310) | (304) | (332) | (381) | (178) | |||||
| Balance, $m | |||||||||||||||
| Balance, $m | Working capital | — | — | — | — | 353 | 1,588 | 1,277 | 838 | 495 | 376 | ||||
| Total debt | — | — | — | — | 17 | 22 | 413 | — | — | — | |||||
| Net debt | — | — | — | — | (364) | (1,528) | (1,316) | (944) | (562) | (423) | |||||
| Shareholders’ equity | — | — | — | — | 470 | 1,567 | 1,736 | 1,097 | 716 | 509 | |||||
| Returns, % | |||||||||||||||
| Returns, % | ROA | — | — | — | 0.00 | (37.51) | (133.28) | (91.31) | (42.47) | (35.96) | (25.05) | ||||
| ROIC | — | — | — | 0.00 | (80.97) | (2,881.62) | (328.33) | (352.92) | (226.46) | (229.21) | |||||
| ROE | — | — | — | 0.00 | (12.88) | (179.64) | (127.43) | (63.02) | (60.34) | (51.08) | |||||
Negative figures in brackets.
Fiscal years to Dec 2025 · latest quarter Jun 2026
Charts ten years each
Ginkgo Bioworks Holdings, Inc. vs peers in Biotechnology (Q) = latest quarter vs a year earlier
| Company | Market cap | P/E | Fwd P/E | Revenue growth (Q) | EPS growth (Q) | FCF growth (Q) | Gross margin (Q) | EBIT margin (Q) | Compare |
|---|---|---|---|---|---|---|---|---|---|
| ALMS Alumis Inc. | $842.4M | — (loss-making) | — (loss-making) | −37.66% (below 0%: shrinking) | n/m | +23.59% (above 0%: growing) | 100.00% | (8,956.38%) | Compare |
| VSTM Verastem, Inc. | $835.9M | — (loss-making) | — (loss-making) | +1,775.43% (above 0%: growing) | n/m | −34.43% (below 0%: shrinking) | 89.92% | (81.62%) | Compare |
| CRVS Corvus Pharmaceuticals, Inc. | $828.6M | — (loss-making) | — | — | n/m | −171.31% (below 0%: shrinking) | 0.00% | 0.00% | Compare |
| AVBP ArriVent BioPharma, Inc. | $827.9M | — (loss-making) | — | — | n/m | −51.51% (below 0%: shrinking) | — | 0.00% | Compare |
| ARDX Ardelyx, Inc. | $814.9M | — (loss-making) | — (loss-making) | +23.77% (above 0%: growing) | n/m | +75.33% (above 0%: growing) | 95.24% | (10.28%) | Compare |
| HELP Cybin Inc. | $807.3M | — (loss-making) | — (loss-making) | — | n/m | −25.60% (below 0%: shrinking) | 0.00% | 0.00% | Compare |
| DNA Ginkgo Bioworks Holdings, Inc. | $791.9M | — (loss-making) | — (loss-making) | −48.49% (below 0%: shrinking) | n/m | −16.38% (below 0%: shrinking) | 91.47% | (290.47%) | |
| GERN Geron Corporation | $790.2M | — (loss-making) | — (loss-making) | +17.22% (above 0%: growing) | n/m | +41.82% (above 0%: growing) | 83.92% | (21.74%) | Compare |
| SANA Sana Biotechnology, Inc. | $740.9M | — (loss-making) | — | — | n/m | −5.46% (below 0%: shrinking) | 0.00% | 0.00% | Compare |
| Median of peers | $821.4M | — | — | +20.50% | — | −15.53% | 83.92% | (5.14%) |
Ginkgo Bioworks Holdings, Inc. (DNA) key facts
- Ginkgo Bioworks Holdings, Inc. (DNA) is a Biotechnology company in the Healthcare sector, listed on the New York Stock Exchange.
- As of October 16, 2026, DNA traded at $10.27, a market capitalization of $791.9 million.
- Return on equity was −51.1% and debt-to-equity 0.00.
- Its Piotroski F-score is 3 out of 9 and its Altman Z-score is −7.61 (distress zone) for fiscal 2025.